Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
Date:10/11/2007

CAMBRIDGE, Mass. and BERLIN /PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with multiple sclerosis (MS) at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) underway in Prague.

Charcot Award Lecture

Top-line, three-year data from a completed international, multi-center, Phase 2 clinical trial known as CAMMS223 that compared alemtuzumab with Rebif(R) (interferon beta-1a) for the treatment of multiple sclerosis will be presented on Sunday, Oct. 14 at 10 a.m. The data will be presented by Professor Alastair Compston during the prestigious Charcot Award lecture. The study results, taken at 36 months, compare alemtuzumab-treated patients with Rebif(R)-treated patients in the risk for sustained accumulation of disability and the risk for relapse. The data come from a pre-specified analysis conducted after three years of treatment for 334 patients in the study.

Details on two poster presentations

-- Alemtuzumab Improved Multiple Sclerosis Functional Composite Scores and

Delayed Time to First Relapse at 2-Year Interim Analysis Compared to

Subcutaneous Interferon Beta 1-a.

Sat. October 13 from 3:30-5:00 p.m. Alasdair J. Coles, M.D.

A further analysis of disability in CAMMS223, as measured by the Multiple Sclerosis Functional Composite Scale (MSFC), will be reported at ECTRIMS. Data from this scale, including quantitative tests on ambulation, manual dexterity, and cognition, will be presented along with new analyses of relapse events. These results build on the two-year analyses of the co-primary endpoints presented at the American Academy of Neurology annual meeting in May, 2007, which demonstrated that the risk of sustained accumulation of disability as well as the annualized relapse rate were m
'/>"/>

SOURCE Genzyme
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients
2. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
3. Bayer Wins Positive Response For Marketing Its Cancer Drug
4. Genomatix Licensed By Bayer Healthcare
5. Bayer to Market Biocon Insulin in China
6. Test for Esophageal Reflux Licensed to Bayer by University
7. Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
8. Dow Acquires Wolff Walsrode from Bayer
9. Asmanex Twisthaler launched by Schering-Plough for treatment of asthma
10. India to benefit from pharma companies move
11. South Africa Wins landmark case against pharmaceutical giants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... In honor of National Take Your Cat to ... & Referral Center of Minnesota (AERC) is offering a few reasons ... cats. , Many people don’t take their cat to the vet ... but they wouldn’t decide not to take their kid to dentist ... same goes for pets. Just like people want their loved ones ...
(Date:9/1/2014)... NV (PRWEB) September 01, 2014 ... and online marketers that was developed to automate the ... caught the attention of Shane Michaels, prompting an investigative ... entrepreneur, the daily duty of managing all of the ... can be quite overwhelming,” reports Michaels. “That’s why Ontraport ...
(Date:9/1/2014)... Hersey, MI (PRWEB) September 01, 2014 Pastor ... Quality Care Specialist at Eagle Village. He is a licensed ... several churches over the past twenty years in New Mexico, ... celebrate 24 years of marriage this year. He also ... He holds a B.S. in Pastoral Ministry from Nazarene Bible ...
(Date:9/1/2014)... US (PRWEB) September 01, 2014 ... view into Heartbeat Experts’ perspectives on ... market. , Download the flash report to ... for any launching Diabetes product:, ... within an increasingly crowded market , ...
(Date:8/31/2014)... The FDA has recently proposed updates ... proposed changes would include more current nutrition values and ... label, and a new design. This change has the ... label. NutriGold fully supports the new changes and believes ... 20 years, it's time for a change,” said Priya ...
Breaking Medicine News(10 mins):Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4
... Can Reveal Blockages Prior to Stroke, CLEVELAND, Oct. ... Kennedy had removed today, are a significant risk factor,for ... the life-threatening,condition. Doppler ultrasound screening is a successful tool ... a stroke and before death or,disability occurs. Life ...
... 12 ABR -- Affinity,BioReagents, a leading global ... website at http://www.bioreagents.com . Re-launched with ... several enhancements which combine to make the customer,s,experience ... to,Ken Wilczek, President of ABR, "We solicited feedback ...
... 50%, study found, , , FRIDAY, Oct. 12 (HealthDay News) -- ... once a week can increase your risk of developing asthma, ... are a direct cause of asthma, or simply a trigger ... this epidemiological study. , However, the European team involved in ...
... Omnicell, Inc.,(Nasdaq: OMCL ), a leading provider of system ... 18 to discuss the,company,s third quarter financial results. What: ... When: October 18, 2007, 2:30 p.m. PDT, ... officer ...
... TO COMMENT ON THE MARKET FORECAST FOR THE DRUG, ... Ph.D., analyst,at Decision Resources, is available to discuss the ... of Merck,s Isentress, the,first integrase inhibitor drug which blocks ... new cells. Integrase inhibitors are a novel class ...
... WARRENDALE, Pa., Oct. 12 Helping its,employees to live ... SAE,International. Recently, the American Heart Association (AHA) recognized,SAE for ... Fit Friendly Company, an honor,presented to only a handful ... What does it mean? In short, it means ...
Cached Medicine News:Health News:Asymptomatic Carotid Artery Blockage a Significant Stroke Risk 2Health News:ABR -- Affinity BioReagents Announces Launch of New Website 2Health News:Home Spray Cleaners Could Raise Asthma Risk 2Health News:Home Spray Cleaners Could Raise Asthma Risk 3Health News:Omnicell Schedules Third Quarter Earnings Call 2Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... GOLDEN, Colo., Nov. 9 ABR-Affinity,BioReagents, a leading ... again exhibit at Medica in Dusseldorf, Germany. ... with over 137,000,visitors expected from all parts of ... BioReagents. The exposure is global, and it is ...
... Nov. 9 This week, Dr. Fouad,Bachour, ... Hennepin County,Medical Center, presented results of a ... http://www.sessionsdailynews.com/tuesday.pdf ) meeting in Orlando showing,that alerting ... a heart attack,patient arrives improves door-to-balloon times ...
Cached Medicine Technology:ABR-Affinity BioReagents to Exhibit in the U.S. Pavilion at Medica, November 14 - 17, 2007 2Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: